Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Mallinckrodt
Harvard Business School
McKinsey
Johnson and Johnson

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

DESOXIMETASONE Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which patents cover Desoximetasone, and when can generic versions of Desoximetasone launch?

Desoximetasone is a drug marketed by Actavis Mid Atlantic, Akorn, Anda Repository, Fougera Pharms, Lupin Atlantis, Perrigo New York, Zydus Pharms, Acp Nimble, Altana, Glenmark Generics, Novel Labs Inc, Perrigo Israel, and Teligent Pharma Inc. and is included in twenty-nine NDAs.

The generic ingredient in DESOXIMETASONE is desoximetasone. There are seven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the desoximetasone profile page.

US ANDA Litigation and Generic Entry Outlook for Desoximetasone

A generic version of DESOXIMETASONE was approved as desoximetasone by PERRIGO NEW YORK on July 1st, 2003.

  Start Trial

Drug patent expirations by year for DESOXIMETASONE
Drug Prices for DESOXIMETASONE

See drug prices for DESOXIMETASONE

Drug Sales Revenue Trends for DESOXIMETASONE

See drug sales revenues for DESOXIMETASONE

Recent Clinical Trials for DESOXIMETASONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPhase 4
Siriraj HospitalPhase 3
Siriraj clinical research centerPhase 3

See all DESOXIMETASONE clinical trials

Recent Litigation for DESOXIMETASONE

Identify potential future generic entrants

District Court Litigation
Case NameDate
TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD.2018-08-08
Taro Pharmaceuticals U.S.A., Inc. v. Perrigo UK FINCO Limited Partnership2015-09-22

See all DESOXIMETASONE litigation

Pharmacology for DESOXIMETASONE
Medical Subject Heading (MeSH) Categories for DESOXIMETASONE
Synonyms for DESOXIMETASONE
(11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
17-Deoxymethansone
17-Desoximethasone
382-67-2
382D672
4E07GXB7AU
9-Fluoro-11-beta,21-dihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
9alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1.4-pregnadiene-3,20-dione
9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone
A 41-304
A 41304
A-41-304
AB2000738
AC1NSJXQ
AKOS030254657
AS-15787
BDBM50103622
BRN 2228097
C-55186
CAS-382-67-2
CCG-101120
CHEBI:691037
CHEMBL1766
CS-3002
CTK8F9086
D03697
DB00547
Deoxymethasone
Desossimetasone
Desossimetasone [DCIT]
Desoximetason
Desoximetasona
Desoximetasona [INN-Spanish]
Desoximetasone (USP/INN)
Desoximetasone [USAN:USP:INN:BAN]
Desoximetasone pound>>A 41-304 pound>>17-deoxy Dexamethasone pound>>HOE 304
Desoximetasonum
Desoximetasonum [INN-Latin]
Desoxymethasone
Dexamethasone Impurity F
DSSTox_CID_25647
DSSTox_GSID_45647
DSSTox_RID_81025
DTXSID3045647
EINECS 206-845-3
Esperson
Flubason
GTPL7067
HMS2052C15
HMS2236H07
HOE 304
HOE-304
HY-17570
Ibaril
MLS000028654
MLS001076073
MLS001424230
MolPort-003-941-111
NC00370
NCGC00023648-03
NCGC00023648-04
Opera_ID_52
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, (11beta,16alpha)-
Q-200938
Q790
R 2113
R-2113
SC-46986
SCHEMBL4214
SMR000058856
Stiedex
Topicort
Topicort (TN)
Topicort LP
Topisolon
Tox21_110889
Tox21_110889_1
UNII-4E07GXB7AU
VWVSBHGCDBMOOT-IIEHVVJPSA-N
ZINC4212854
Paragraph IV (Patent) Challenges for DESOXIMETASONE
Tradename Dosage Ingredient NDA Submissiondate
TOPICORT SPRAY;TOPICAL desoximetasone 204141 2013-12-18

US Patents and Regulatory Information for DESOXIMETASONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Atlantis DESOXIMETASONE desoximetasone SPRAY;TOPICAL 208124-001 Mar 16, 2018 AT RX No No   Start Trial   Start Trial   Start Trial
Perrigo Israel DESOXIMETASONE desoximetasone SPRAY;TOPICAL 206441-001 Jan 20, 2017 AT RX No No   Start Trial   Start Trial   Start Trial
Actavis Mid Atlantic DESOXIMETASONE desoximetasone CREAM;TOPICAL 205082-001 Sep 4, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Anda Repository DESOXIMETASONE desoximetasone OINTMENT;TOPICAL 204272-001 Nov 30, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Perrigo Israel DESOXIMETASONE desoximetasone OINTMENT;TOPICAL 077770-001 Apr 20, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Lupin Atlantis DESOXIMETASONE desoximetasone CREAM;TOPICAL 208163-001 Jan 10, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Anda Repository DESOXIMETASONE desoximetasone CREAM;TOPICAL 210980-001 Dec 21, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Dow
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.